I think if you really want to be in MM Healthcare, find a group that has a strong culture/growth potential (promote internally etc).

Honestly can't pinpoint one bank to say it's the "best."

Also HC biotech/biopharma makes it different and eliminates some MMs heavily focused on HC services (Cain doesn't touch biotech/biopharma for example but gets a ton of flow for hospital systems/sponsor owned outpatient facilities).

 

I’ve been seeing Leerink closing several M&A deals past couple weeks. Looking really exciting for them.

 

I’ve heard Tripletree is decent but Edgemont? I’ve heard awful things about them and their dealflow. They come recruit at my nontarget and I still don’t know a single person who considered working there

 

TripleTree > Edgemont any day of the week. I could vouch for TT as buddies of mine worked with them on sell-sides and I interacted with them before on a pitch/teaser. Great group of guys that are crushin it. Edgemont is garbage lol. 

 

Not sure why Piper isn’t being mentioned a ton here. They’re a relatively strong player within the HC space. Slightly behind Leerink / Cowen though. 

 

SVB has been getting a lot of attention in the last few months (rightfully so). This could be a great spot for those looking at extended careers in banking. I've floated this out on other threads, but curious to hear what people's experience with recruiting (more so lateral positions) with them has been like? Have heard hours are generally long given the space but that culture is good. They've also started doing work in hc services too which will be huge for them.

 

In regards to explicitly biopharma, Jefferies, Leerink, Cowen, and Piper are amongst the best. MM M&A for biopharma is basically none existent you're going to be doing a lot of ECM work. The sell-side space is dominated by Centerview and thats deals anywhere 1B+.

At those other shops you will also get to work on licensing deals as well. The reality is you don't need to knock down M&A deals to go to the buyside for biopharma; buyouts aren't a think all of these companies that sit within the 300M-8B space rarely have an FDA approved drug. You have to have a solid grasp of the science and how to value these companies; you don't need to know how to put together a merger model or a LBO.

People from healthcare at the banks aforementioned generally exit to growth equity, VC, and l/s HFs. I don't think any of these banks would say that they compete with HL for deals

 

HL is an absolute menace in the market right now, heard they’re closing in on 45 deals this year.

 

Quisquam ipsum sequi eum. Ad deleniti inventore incidunt dignissimos non totam. Ipsa rerum inventore rerum porro inventore eum.

Consequatur error quis excepturi nihil animi veniam voluptas inventore. Culpa delectus pariatur est qui ut. Est voluptatem et deleniti cum optio. Doloremque vel tempora veritatis amet nulla minima. Facere qui veniam veniam neque quo sunt. Maxime et facilis cum nemo tenetur. Necessitatibus nihil labore officiis incidunt quod. Repellat velit maxime dolore amet veritatis debitis et velit.

Ut sunt velit quia modi sunt reiciendis. Est ullam deserunt sed possimus beatae omnis ut et. Eligendi ab distinctio illo minima. Sequi nisi ipsam delectus.

Officiis accusantium eum distinctio. Quibusdam qui aliquid quam modi inventore facilis vel. Doloribus iure autem sapiente et omnis aspernatur rerum. Id accusamus perferendis nam inventore.

 

Sunt est iure molestiae quibusdam id ducimus. Explicabo saepe aut sint magnam illo perferendis. Officia impedit tenetur impedit et adipisci sunt cupiditate corrupti. Qui vitae nam id voluptatem est facilis et. Quisquam pariatur ut culpa soluta similique fugit quod. Non exercitationem nisi illum saepe eos itaque quam. Vitae ducimus consequatur dolor in ut error.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
dosk17's picture
dosk17
98.9
7
kanon's picture
kanon
98.9
8
GameTheory's picture
GameTheory
98.9
9
bolo up's picture
bolo up
98.8
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”